170851-70-4

Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.

Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus, but was discontinued due to lack of efficacy.Ipamorelin has been used by athletes as a performance enhancing drug.

Ipamorelin has a wide range of benefits for the human body such as: reduced body fat, increased collagen production, increased lean muscle mass, improved sleep, increased cell repair and regeneration, elevated IGF-1, increased bone mineral content, counteracted glucocorticoid catabolism, decreased appetite stimulation compared to GHRP-6, decreased release of cortisol, prolactin and aldosterone. Decreased release of cortisol, prolactin and aldosterone.

Ipamorelin is generally considered safe and well tolerated, with common side effects including dizziness, headache, nausea, diarrhoea and flushing. Allergic or serious adverse reactions are rare.